Cyclosporin A therapy for interstitial pneumonitis associated with rheumatic disease
Cyclosporin A therapy for interstitial pneumonitis associated with rheumatic disease
复制标题
环孢素 A 治疗风湿病相关间质性肺炎
DOI:
10.3109/s101650200054
复制
发表时间:
2002
影响因子:
2.2
通讯作者:
H. Hashimoto
中科院分区:
文献类型:
--
作者:
Y. Tokano;H. Ogasawara;S. Ando;T. Fujii;H. Kaneko;N. Tamura;T. Yano;K. Hirokawa;T. Fukazawa;A. Murashima;S. Kobayashi;I. Sekigawa;Y. Takasaki;N. Iida;H. Hashimoto
Abstract To determine the efficacy of cyclosporin A (CysA) for the treatment of steroid-resistant interstitial pneumonitis (IP), we enrolled 25 patients with various rheumatic diseases and steroid-resistant IP in a pilot study [4 patients with rheumatoid arthritis (RA), 2 with systemic lupus erythematosus (SLE), 11 with polymyositis/dermatomyositis (PM/DM), 4 with systemic sclerosis (SSc), 1 with mixed connective tissue disease (MCTD), 3 with Sjögren syndrome (SS)]. Twelve patients (48%) showed a persistent response to CysA therapy, and 7 of them had PM/DM, including so-called amyopathic DM. Patients with a persistent response had moderately elevated lactate dehydroxygenase (LDH) levels, whereas patients who died had much higher LDH levels and hypoxia. Even patients with low blood levels of CysA achieved a persistent response. In responding patients, the symptoms, chest X-ray findings, arterial oxygen tension, and LDH level all improved after less than 4 weeks. In conclusion, CysA seem to be useful for treating patients with steroid-resistant IP, whose duration is short and severity is mild.